Clinical use of plasma and plasma fractions.
Best Pract Res Clin Haematol
; 19(1): 83-96, 2006.
Article
en En
| MEDLINE
| ID: mdl-16377543
The use of plasma and plasma-derived products has always involved a careful balance of anticipated benefit versus risk. Risk reduction through pathogen-inactivated products has been successful, but the expense of manufacture does not warrant widespread use. Although plasma has always had limited indications for use, these are often misunderstood or ignored in favor of received knowledge and tradition. Solid evidence from multiple trials support the limited indications for FFP described here and support products that target specific coagulation defects.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Plasma
/
Factores de Coagulación Sanguínea
/
Transfusión de Componentes Sanguíneos
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Best Pract Res Clin Haematol
Asunto de la revista:
HEMATOLOGIA
Año:
2006
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Países Bajos